UPDATED British Prime Minister Theresa May is to announce plans to commit millions of pounds to a new artificial intelligence strategy for early-stage cancer diagnosis. The aim is to reduce deaths from prostate, ovarian, lung, and bowel cancer by 10 percent within 15 years – saving an estimated 22,000 lives a year. In the first of a new series of speeches on the UK's industrial strategy, the prime minister will say, "Late diagnosis of otherwise treatable illnesses is one of the biggest causes of avoidable deaths. "The development of smart technologies to analyse great quantities of data quickly and with a higher degree of accuracy than is possible by human beings, opens up a whole new field of medical research, and gives us a new weapon in our armoury in the fight against disease." May is expected to ask the technology industry and cancer charities to work with the NHS to develop new algorithms that can use a mix of patient data, genetic markers, and lifestyle information to warn GPs of the risk of common cancers developing. News of the government's strategy comes on the same day that the Royal Liverpool and Broadgreen University Hospitals NHS Trust announced that it has embarked on a new AI programme to improve the treatment of patients who have had a heart attack, in a project that could see wider use of AI to inform treatment decisions across the organisation. The Trust, which was named as the NHS' Global Digital Exemplar of the year, will use technology from healthcare specialist, Deontics. The new system will enable doctors on the Trust's acute cardiac unit (ACU) to access AI-driven evidence-based clinical treatment recommendations that are tailored to each patient's needs. Deontics uses cognitive computing and healthcare-specific logic to act like a "clinical sat-nav" for doctors, according to a joint announcement this morning. This enables them to make treatment decisions that are dynamically informed by relevant standards and guidelines, such as those issued by NICE, and the latest good practice from published papers and other reputable sources. These are then applied directly to the needs of individual patients. "Some of our most frail and elderly patients with acute coronary syndrome are getting some of our most powerful drugs," explained the Trust's chief clinical information officer, Mike Fisher. "Using AI-technology means we should reduce the potential for overprescribing drugs for patients at lower levels of risk.